免疫检查点抑制剂联合或不联合放疗治疗黑色素瘤脑转移:系统综述与Meta分析
该系统综述与Meta分析纳入11项研究共14个队列,评估ICI联合治疗、ICI联合放疗与ICI单药治疗黑色素瘤脑转移的颅内客观缓解率、疾病控制率及不良事件。ICI联合治疗和ICI联合放疗的局部疗效均高于ICI单药,但ICI联合治疗的3/4级不良事件率最高,中枢神经系统相关3/4级事件率组间相似。
要点
- ICI联合放疗的颅内DCR达85%,高于ICI单药的26%和ICI联合治疗的57%。
- ICI联合治疗颅内ORR为53%,ICI联合放疗为42%,ICI单药为15%。
- ICI联合治疗3/4级不良事件率60%,高于ICI单药的11%和ICI联合放疗的4%。
核心结论
- ICI联合治疗或ICI联合放疗治疗黑色素瘤脑转移的局部疗效优于ICI单药治疗。
- ICI联合治疗的3/4级不良事件率最高,而中枢神经系统相关3/4级事件率各组相似。
- 作者认为需前瞻性试验比较ICI联合治疗与ICI联合放疗的疗效。
研究设计与样本
- 系统综述与Meta分析,检索Ovid-MEDLINE和EMBASE截至2019年10月12日。
- 纳入评估ICI联合或不联合放疗治疗黑色素瘤脑转移颅内ORR和/或DCR的研究。
- 共纳入11项研究14个队列:ICI联合治疗3个、ICI联合放疗5个、ICI单药6个。
诊断标准与关键数值
- ICI联合治疗:合并ORR 53%(95%CI 44-61%),DCR 57%(95%CI 49-66%)。
- ICI联合放疗:合并ORR 42%(95%CI 31-54%),DCR 85%(95%CI 63-95%)。
- ICI单药:合并ORR 15%(95%CI 11-20%),DCR 26%(95%CI 21-32%)。
- 3/4级不良事件率:ICI联合治疗60%(95%CI 52-67%),ICI单药11%(95%CI 8-17%),ICI联合放疗4%(95%CI 1-19%)。
- 3/4级中枢神经系统相关不良事件率:ICI联合治疗9%,ICI联合放疗8%,ICI单药5%,组间无差异。
临床应用与阅片要点
- 阅片评估黑色素瘤脑转移疗效时,可参考ICI联合治疗或ICI联合放疗较ICI单药有更高的颅内ORR和DCR。
- ICI联合治疗组3/4级不良事件率较高,ICI联合放疗组较低,评估时需结合临床安全性信息。
局限性
- 作者指出需前瞻性试验比较ICI联合治疗与ICI联合放疗的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Immune checkpoint inhibitor (ICI) therapy has shown activity against melanoma brain metastases. Recently, promising results have also been reported for ICI combination therapy and ICI combined with radiotherapy. We aimed to evaluate radiologic response and adverse event rates of these therapeutic options by a systematic review and meta-analysis.
MATERIALS AND METHODS: A systematic literature search of Ovid-MEDLINE and EMBASE was performed up to October 12, 2019 and included studies evaluating the intracranial objective response rates (ORRs) and/or disease control rates (DCRs) of ICI with or without radiotherapy for treating melanoma brain metastases. We also evaluated safety-associated outcomes.
RESULTS: Eleven studies with 14 cohorts (3 with ICI combination therapy; 5 with ICI combined with radiotherapy; 6 with ICI monotherapy) were included. ICI combination therapy {pooled ORR, 53% (95% confidence interval [CI], 44-61%); DCR, 57% (95% CI, 49-66%)} and ICI combined with radiotherapy (pooled ORR, 42% [95% CI, 31-54%]; DCR, 85% [95% CI, 63-95%]) showed higher local efficacy compared to ICI monotherapy (pooled ORR, 15% [95% CI, 11-20%]; DCR, 26% [95% CI, 21-32%]). The grade 3 or 4 adverse event rate was significantly higher with ICI combination therapy (60%; 95% CI, 52-67%) compared to ICI monotherapy (11%; 95% CI, 8-17%) and ICI combined with radiotherapy (4%; 95% CI, 1-19%). Grade 3 or 4 central nervous system (CNS)-related adverse event rates were not different (9% in ICI combination therapy; 8% in ICI combined with radiotherapy; 5% in ICI monotherapy).
CONCLUSION: ICI combination therapy or ICI combined with radiotherapy showed better local efficacy than ICI monotherapy for treating melanoma brain metastasis. The grade 3 or 4 adverse event rate was highest with ICI combination therapy, and the CNS-related grade 3 or 4 event rate was similar. Prospective trials will be necessary to compare the efficacy of ICI combination therapy and ICI combined with radiotherapy.
引用
- Kim PH, Suh CH, Kim HS, et al. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Korean J Radiol. 2020. PMID: 33289357. doi:10.3348/kjr.2020.0728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。